Penumbra Inc (PEN) stock
PENNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 15/3074% above fair value
$320.62−0.29 (-0.09%)
Close on Nov 16, 2026Market cap $12.64BP/E 80.8Yield –
Penumbra r&d expenses
Research and development expenses are spending on new products and technology.
Penumbra's R&D Expenses for the twelve months ending Sep 30, 2026 was $94.93M, up 7.9% year over year. For fiscal 2025 it was $89.77M, down 5.3% from the year before. Over ten years it grew 17.4% a year on average. The highest annual figure on record is $104.55M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $89.77M | -5.3% |
| FY2024 | Dec 31, 2024 | $94.78M | +12.3% |
| FY2023 | Dec 31, 2023 | $84.42M | +6.3% |
| FY2022 | Dec 31, 2022 | $79.41M | -24.1% |
| FY2021 | Dec 31, 2021 | $104.55M | +16.1% |
| FY2020 | Dec 31, 2020 | $90.05M | +74.1% |
| FY2019 | Dec 31, 2019 | $51.72M | +43.0% |
| FY2018 | Dec 31, 2018 | $36.17M | +14.2% |
| FY2017 | Dec 31, 2017 | $31.66M | +32.6% |
| FY2016 | Dec 31, 2016 | $23.88M | +32.4% |
| FY2015 | Dec 31, 2015 | $18.03M | +15.7% |
| FY2014 | Dec 31, 2014 | $15.58M | +10.6% |
| FY2013 | Dec 31, 2013 | $14.08M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $25.36M | +11.8% |
| Q2 FY2026 | Jun 30, 2026 | $25.40M | +9.4% |
| Q1 FY2026 | Mar 31, 2026 | $22.38M | +1.4% |
| Q4 FY2025 | Dec 31, 2025 | $21.79M | +8.9% |
| Q3 FY2025 | Sep 30, 2025 | $22.68M | -10.0% |
| Q2 FY2025 | Jun 30, 2025 | $23.22M | -6.9% |
| Q1 FY2025 | Mar 31, 2025 | $22.08M | -10.4% |
| Q4 FY2024 | Dec 31, 2024 | $20.01M | -8.8% |
| Q3 FY2024 | Sep 30, 2024 | $25.21M | +20.3% |
| Q2 FY2024 | Jun 30, 2024 | $24.94M | +15.8% |
| Q1 FY2024 | Mar 31, 2024 | $24.63M | +23.2% |
| Q4 FY2023 | Dec 31, 2023 | $21.94M | +22.1% |
| Q3 FY2023 | Sep 30, 2023 | $20.96M | -1.7% |
| Q2 FY2023 | Jun 30, 2023 | $21.54M | +10.1% |
| Q1 FY2023 | Mar 31, 2023 | $19.99M | -2.8% |
| Q4 FY2022 | Dec 31, 2022 | $17.96M | -65.5% |
| Q3 FY2022 | Sep 30, 2022 | $21.32M | +27.4% |
| Q2 FY2022 | Jun 30, 2022 | $19.56M | +10.3% |
| Q1 FY2022 | Mar 31, 2022 | $20.56M | +13.8% |
| Q4 FY2021 | Dec 31, 2021 | $52.00M | +167.3% |
| Q3 FY2021 | Sep 30, 2021 | $16.73M | -52.1% |
| Q2 FY2021 | Jun 30, 2021 | $17.74M | -21.9% |
| Q1 FY2021 | Mar 31, 2021 | $18.08M | +39.6% |
| Q4 FY2020 | Dec 31, 2020 | $19.46M | +51.3% |
| Q3 FY2020 | Sep 30, 2020 | $34.92M | +154.3% |
| Q2 FY2020 | Jun 30, 2020 | $22.73M | +68.8% |
| Q1 FY2020 | Mar 31, 2020 | $12.95M | +11.0% |
| Q4 FY2019 | Dec 31, 2019 | $12.86M | +18.3% |
| Q3 FY2019 | Sep 30, 2019 | $13.73M | +51.0% |
| Q2 FY2019 | Jun 30, 2019 | $13.46M | +64.3% |
| Q1 FY2019 | Mar 31, 2019 | $11.67M | +45.6% |
| Q4 FY2018 | Dec 31, 2018 | $10.87M | +29.4% |
| Q3 FY2018 | Sep 30, 2018 | $9.09M | +11.8% |
| Q2 FY2018 | Jun 30, 2018 | $8.19M | +1.2% |
| Q1 FY2018 | Mar 31, 2018 | $8.01M | +13.9% |
| Q4 FY2017 | Dec 31, 2017 | $8.40M | +37.4% |
| Q3 FY2017 | Sep 30, 2017 | $8.13M | – |
| Q2 FY2017 | Jun 30, 2017 | $8.09M | – |
| Q1 FY2017 | Mar 31, 2017 | $7.03M | – |
| Q4 FY2016 | Dec 31, 2016 | $6.11M | – |
See a number that looks wrong?